J. Hood

发表

Differential αv integrin–mediated Ras-ERK signaling during two pathways of angiogenesis

David A. Cheresh, Martin A. Schwartz, M. Schwartz, 2003, The Journal of cell biology.

Tumor Regression by Targeted Gene Delivery to the Neovasculature

M. Bednarski, D. Cheresh, J. Hood, 2002, Science.

Induction of Angiogenesis by a Fragment of Human Tyrosyl-tRNA Synthetase*

P. Schimmel, K. Ewalt, D. Cheresh, 2002, The Journal of Biological Chemistry.

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

Sandra A. Moore, Y. Ko, R. Levine, 2008, Cancer cell.

Isoform-selective PI3K inhibitors as novel therapeutics for the treatment of acute myocardial infarction.

G. Noronha, W. Wrasidlo, J. Hood, 2007, Biochemical Society transactions.

Isoform-selective PI 3 K inhibitors as novel therapeutics for the treatment of acute myocardial infarction

G. Noronha, W. Wrasidlo, J. Hood, 2007 .

Protein Kinase G Mediates Vascular Endothelial Growth Factor-induced Raf-1 Activation and Proliferation in Human Endothelial Cells*

H. Granger, J. Hood, H J Granger, 1998, The Journal of Biological Chemistry.

TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations

D. Gilliland, G. Noronha, D. Gilliland, 2007, Leukemia.

A fragment of human TrpRS as a potent antagonist of ocular angiogenesis

P. Schimmel, K. Ewalt, D. Cheresh, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Src-mediated coupling of focal adhesion kinase to integrin αvβ5 in vascular endothelial growth factor signaling

D. Sheppard, D. Schlaepfer, D. Stupack, 2002, The Journal of cell biology.

Stretch-activated single-channel and whole cell currents in vascular smooth muscle cells.

M. J. Davis, J. Hood, J. Donovitz, 1992, The American journal of physiology.

VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells.

H. Granger, M. Ziche, J. Hood, 1998, The American journal of physiology.

Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury.

G. Noronha, W. Wrasidlo, D. Cheresh, 2006, Proceedings of the National Academy of Sciences of the United States of America.

Phosphoinositide 3-kinase γ/δ inhibition limits infarct size after myocardial ischemia/reperfusion injury

G. Noronha, W. Wrasidlo, D. Cheresh, 2006, Proceedings of the National Academy of Sciences.

of the JAK2 pathway Mechanisms of endothelial cell protection by blockade

S. Rivella, J. Gerdes, M. Cappellini, 2010 .

Fedratinib in myelofibrosis.

R. Mesa, C. Harrison, J. Hood, 2020, Blood advances.

Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors.

G. Noronha, Annelie Abrahamsson, J. Durocher, 2008, Cancer cell.

Roles of Adenosine in Angiogenesis

H. Granger, M. Ziche, J. Hood, 1998 .

Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalassemia.

S. Rivella, J. Gerdes, M. Cappellini, 2008, Blood.

European Bioanalysis Forum recommendation on singlicate analysis for ligand binding assays: time for a new mindset.

J. Hood, P. Timmerman, M. Barfield, 2020, Bioanalysis.

erythropoiesis in Decreased differentiation of erythroid cells exacerbates ineffective

S. Rivella, J. Gerdes, M. Cappellini, 2008 .

Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer

J. Hood, R. Wilkinson, N. Luheshi, 2021, mAbs.

Role of Raf in Vascular Protection from Distinct Apoptotic Stimuli

D. Stupack, D. Cheresh, J. Hood, 2003, Science.

Differential (cid:2) v integrin–mediated Ras-ERK signaling during two pathways of angiogenesis

M. Schwartz, D. Cheresh, J. Hood, 2003 .

TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients

D. Gilliland, S. Verstovsek, A. Tefferi, 2008, Leukemia.

The design and preliminary structure-activity relationship studies of benzotriazines as potent inhibitors of Abl and Abl-T315I enzymes.

G. Noronha, Xinshan Kang, J. Hood, 2007, Bioorganic & medicinal chemistry letters.

A Small-Molecule Inhibitor of the Wnt Pathway, Lorecivivint (SM04690), as a Potential Disease-Modifying Agent for the Treatment of Degenerative Disc Disease.

J. Hood, Y. Yazici, M. Ibanez, 2020, The spine journal : official journal of the North American Spine Society.

A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study.

M. Hochberg, N. Lane, J. Hood, 2017, Osteoarthritis and cartilage.

Metabolism and Pharmacokinetics of a Novel Src Kinase Inhibitor TG100435 ([7-(2,6-Dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]- [4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine) and Its Active N-Oxide Metabolite TG100855 ([7-(2,6-Dichloro-phenyl)-5-methyl- benzo[1,2,4]triazin-3-yl]-{4-[2-(1-oxy-py

G. Noronha, J. Hood, R. Soll, 2007 .

TG 101209 , a small molecule JAK 2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK 2 V 617 F and MPL W 515 L / K mutations

D. Gilliland, G. Noronha, R. Mesa, 2007 .

Jak2 inhibition deactivates Lyn kinase through the SET–PP2A–SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients

Yan Wang, H. Kantarjian, D. Perrotti, 2009, Oncogene.

Discovery of 3,3'-(2,4-diaminopteridine-6,7-diyl)diphenol as an isozyme-selective inhibitor of PI3K for the treatment of ischemia reperfusion injury associated with myocardial infarction.

G. Noronha, Xinshan Kang, W. Wrasidlo, 2007, Journal of medicinal chemistry.

Inhibitors of ABL and the ABL-T315I mutation.

G. Noronha, Xinshan Kang, J. Hood, 2008, Current topics in medicinal chemistry.

SM04755, a small‐molecule inhibitor of the Wnt pathway, as a potential topical treatment for tendinopathy

J. Hood, C. Barroga, Y. Yazici, 2020, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

Role of integrins in cell invasion and migration

David A. Cheresh, D. Cheresh, J. Hood, 2002, Nature Reviews Cancer.

Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment.

B. Melchior, Ch Lai, J. Hood, 2019, Osteoarthritis and cartilage.

A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee.

J. Hood, C. Barroga, M. Ibanez, 2018, Osteoarthritis and cartilage.

A human aminoacyl-tRNA synthetase as a regulator of angiogenesis

P. Schimmel, K. Ewalt, D. Cheresh, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability.

P. Schwartzberg, D. Cheresh, J. Hood, 1999, Molecular cell.

Nitric Oxide Is an Upstream Signal of Vascular Endothelial Growth Factor-induced Extracellular Signal-regulated Kinase½ Activation in Postcapillary Endothelium*

H. Granger, L. Morbidelli, M. Ziche, 1998, The Journal of Biological Chemistry.

In Vitro and In Vivo Inhibition of the T315I Mutant BCR/ABL Kinase.

A. McPherson, G. Noronha, J. Hood, 2006 .

Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration.

Hong Zhu, Steven Hu, Joel Renick, 2008, Journal of medicinal chemistry.

Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays.

Hong Zhu, Feng Shi, Steven Hu, 2007, Bioorganic & medicinal chemistry letters.

Discovery and preliminary structure-activity relationship studies of novel benzotriazine based compounds as Src inhibitors.

Joel Renick, Kathy Barrett, Richard Soll, 2006, Bioorganic & medicinal chemistry letters.

Pharmacokinetic-Pharmacodynamic Modelling of Systemic IL13 Blockade by Monoclonal Antibody Therapy: A Free Assay Disguised as Total

P. Vicini, J. Hood, I. González-García, 2021, Pharmaceutics.

Metabolism and Pharmacokinetics of a Novel Src Kinase Inhibitor TG100435 ([7-(2,6-Dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine) and Its Active N-Oxide Metabolite TG100855 ([7-(2,6-Dichloro-phenyl)-5-methylbenzo[1,2,4]triazin-3-yl]-{4-[2-(1-oxy-pyrro

Joel Renick, Richard Soll, G. Noronha, 2007, Drug Metabolism and Disposition.

Building a better Trap

D. Cheresh, J. Hood, 2003, Proceedings of the National Academy of Sciences of the United States of America.

A Dominant-Negative p65 PAK Peptide Inhibits Angiogenesis

M. Gerritsen, M. Schwartz, D. Cheresh, 2002, Circulation research.

The TGF-β inhibitory activity of antibody 37E1B5 depends on its H-CDR2 glycan

J. Hood, R. Dunmore, N. Bond, 2017, mAbs.

SC 23992: radioreceptor assays for therapeutic and side effects.

J. Hood, J. Funder, J. Mercer, 1976, Clinical science and molecular medicine. Supplement.

TG101209, a Selective JAK2 Kinase Inhibitor, Suppresses Endogenous and Cytokine-Supported Colony Formation from Hematopoietic Progenitors Carrying JAK2V617F or MPLW515K/L Mutations.

G. Noronha, R. Mesa, A. Tefferi, 2006 .

Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412.

R. Thorpe, J. Hood, C. Ball, 2010, Journal of immunological methods.

Primary Cell Experiments with TG101348, a JAK2-Selective Inhibitor, in the Presence of Myeloproliferative Disorder-Associated JAK2V617F, MPLW515L/K, and JAK2 Exon 12 Mutations.

G. Noronha, H. Kantarjian, J. Cortes, 2007 .

Controlling the bioactivity of a peptide hormone in vivo by reversible self-assembly

David Baker, M. Welland, P. Vicini, 2017, Nature Communications.

VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells.

H. Granger, M. Ziche, J. Hood, 1998, American journal of physiology. Heart and circulatory physiology.

Exon-exon junction--what's your function?

J. Hood, 2001, Trends in cell biology.

Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits.

G. Noronha, R. Gariano, D. Cheresh, 2008, The Journal of clinical investigation.

Peptidomics of enteroendocrine cells and characterisation of potential effects of a novel preprogastrin derived-peptide on glucose tolerance in lean mice

F. Reimann, F. Gribble, C. Ämmälä, 2021, Peptides.

Topical administration of a multi‐targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema

P. Campochiaro, G. Noronha, J. Hood, 2008, Journal of cellular physiology.

Case Series of Potential Wernicke's Encephalopathy in Patients Treated with Fedratinib

J. Brewer, R. Mesa, C. Harrison, 2017 .

Controlling the bioactivity of a peptide hormone in vivo by reversible self-assembly

David Baker, M. Welland, P. Vicini, 2017, Nature Communications.

Targeted delivery of mutant Raf kinase to neovessels causes tumor regression.

D. Cheresh, J. Hood, 2002, Cold Spring Harbor symposia on quantitative biology.

Discovery of a small molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying treatment for knee osteoarthritis

J. Hood, Y. Hu, C. Barroga, 2016 .